CGEN Projected Dividend Yield
Ord/Compugen Ltd ( NASDAQ : CGEN )Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery capabilities to identify drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Co.'s immuno-oncology pipeline consists of four clinical stage programs, COM701, which is an anti-PVRIG antibody, for the treatment of solid tumors; COM902, which is a therapeutic antibody targeting TIGIT; Bapotulimab, which is an antibody targeting ILDR2; and AZD2936, which is an anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Co.'s COM902 program. 20 YEAR PERFORMANCE RESULTS |
CGEN Dividend History Detail CGEN Dividend News CGEN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |